Effect of Afrezza on Glucose Dynamics During HCL Treatment

被引:18
作者
Galderisi, Alfonso [1 ,2 ]
Cohen, Nathan [3 ]
Calhoun, Peter [3 ]
Kraemer, Kristen [1 ]
Breton, Marc [4 ]
Weinzimer, Stuart [1 ]
Cengiz, Eda [1 ,5 ]
机构
[1] Yale Sch Med, Dept Pediat, New Haven, CT 06510 USA
[2] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy
[3] Jaeb Ctr Hlth Res, Tampa, FL USA
[4] Univ Virginia, Ctr Diabet Technol, Charlottesville, VA USA
[5] Bahcesehir Univ, Sch Med, Istanbul, Turkey
关键词
CLOSED-LOOP CONTROL; POSTPRANDIAL GLUCOSE; GLYCEMIC EXCURSIONS; INSULIN DELIVERY; CONTROL; 1ST; PRAMLINTIDE; GLUCAGON; FEASIBILITY; FASTER; ASPART;
D O I
10.2337/dc20-0091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE A major obstacle in optimizing the performance of closed-loop automated insulin delivery systems has been the delay in insulin absorption and action that results from the subcutaneous (SC) route of insulin delivery leading to exaggerated postmeal hyperglycemic excursions. We aimed to investigate the effect of Afrezza inhaled insulin with ultrafast-in and -out action profile on improving postprandial blood glucose control during hybrid closed-loop (HCL) treatment in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS We conducted an inpatient, three-way, randomized crossover standardized meal study to assess the efficacy and safety of Afrezza at a low (A(L)) and a high (A(H)) dose as compared with a standard SC rapid-acting insulin (aspart) premeal bolus during Diabetes Assistant (DiAs) HCL treatment. Participants received two sequential meals on three study days, and premeal insulin bolus was determined based on home insulin-to-carbohydrate ratio for each meal (rounded up to the closest available Afrezza cartridge dose for A(H)and down for A(L)). The primary efficacy outcome was the peak postprandial plasma glucose (PPG) level calculated by pooling data for up to 4 h after the start of each meal. Secondary outcomes included hyperglycemic, hypoglycemic, and euglycemic venous glucose metrics. RESULTS The mean +/- SD PPG for the rapid-acting insulin control arm and A(H)was similar (185 +/- 50 mg/dL vs. 195 +/- 46 mg/dL, respectively;P= 0.45), while it was higher for meals using A(L)(208 +/- 54 mg/dL,P= 0.04). The A(H)achieved significantly lower early PPG level than the control arm (30 min;P< 0.001), and improvement in PPG waned at later time points (120 and 180 min;P= 0.02) coinciding with the end of Afrezza glucodynamic action. CONCLUSIONS Afrezza (A(H)) premeal bolus reduced the early glycemic excursion and improved PPG during HCL compared with aspart premeal bolus. The improvement in PPG was not sustained after the end of Afrezza glucodynamic action at 120 min.
引用
收藏
页码:2146 / 2152
页数:7
相关论文
共 29 条
[1]   Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study [J].
Akturk, Halis Kaan ;
Snell-Bergeon, Janet K. ;
Rewers, Amanda ;
Klaff, Leslie J. ;
Bode, Bruce W. ;
Peters, Anne L. ;
Bailey, Timothy S. ;
Garg, Satish K. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (10) :639-647
[2]   Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes [J].
Akturk, Halis Kaan ;
Rewers, Amanda ;
Joseph, Hal ;
Schneider, Nicole ;
Garg, Satish K. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 :24-32
[3]   Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial [J].
Bode, Bruce W. ;
McGill, Janet B. ;
Lorber, Daniel L. ;
Gross, Jorge L. ;
Chang, P. -C. ;
Bregman, David B. .
DIABETES CARE, 2015, 38 (12) :2266-2273
[4]  
Cengiz E, 2013, PANMINERVA MED, V55, P269
[5]   Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming [J].
Cengiz, Eda ;
Weinzimer, Stuart A. ;
Sherr, Jennifer L. ;
Tichy, Eileen M. ;
Carria, Lori ;
Cappiello, Darryll ;
Steffen, Amy ;
Tamborlane, William V. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (01) :20-25
[6]   Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device [J].
Cengiz, Eda ;
Weinzimer, Stuart A. ;
Sherr, Jennifer L. ;
Tichy, Eileen ;
Martin, Melody ;
Carria, Lori ;
Steffen, Amy ;
Tamborlane, William V. .
PEDIATRIC DIABETES, 2013, 14 (03) :168-173
[7]   Postprandial glucose regulation and diabetic complications [J].
Ceriello, A ;
Hanefeld, M ;
Leiter, L ;
Monnier, L ;
Moses, A ;
Owens, D ;
Tajima, N ;
Tuomilehto, J .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (19) :2090-2095
[8]   Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial [J].
Dovc, Klemen ;
Piona, Claudia ;
Mutlu, Guel Yesiltepe ;
Bratina, Natasa ;
Bizjan, Barbara Jenko ;
Lepej, Dusanka ;
Nimri, Revital ;
Atlas, Eran ;
Muller, Ido ;
Kordonouri, Olga ;
Biester, Torben ;
Danne, Thomas ;
Phillip, Moshe ;
Battelino, Tadej .
DIABETES CARE, 2020, 43 (01) :29-36
[9]   The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes [J].
Fredheim, Siri ;
Andersen, Marie-Louise M. ;
Porksen, Sven ;
Nielsen, Lotte B. ;
Pipper, Christian ;
Hansen, Lars ;
Holst, Jens J. ;
Thomsen, Jane ;
Johannesen, Jesper ;
Mortensen, Henrik B. ;
Svensson, Jannet .
DIABETOLOGIA, 2015, 58 (04) :828-834
[10]   Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes [J].
Galderisi, Alfonso ;
Sherr, Jennifer ;
VanName, Michelle ;
Carria, Lori ;
Zgorski, Melinda ;
Tichy, Eileen ;
Weyman, Kate ;
Cengiz, Eda ;
Weinzimer, Stuart ;
Tamborlane, William .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (03) :1088-1094